ImmuPharma plc (LON:IMM – Get Free Report)’s stock price dropped 25.5% during mid-day trading on Monday . The company traded as low as GBX 6.76 and last traded at GBX 7.27. Approximately 24,809,416 shares traded hands during mid-day trading, an increase of 211% from the average daily volume of 7,971,064 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Down 31.4%
The company has a 50-day moving average of GBX 11.18 and a 200 day moving average of GBX 5.81. The stock has a market capitalization of £33.68 million, a PE ratio of -7.53 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- What to Know About Investing in Penny Stocks
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
- What is a Death Cross in Stocks?
- Why Circle Stock Is Falling—and Why Some Analysts See Big Upside
- 3 Monster Growth Stocks to Buy Now
- NVIDIA Nears Buy Zone as Rumors Swirl About China Chip Deal
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
